Theravance Biopharma TBPH reported first-quarter 2025 adjusted net loss of 17 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 11 cents. In the year-ago quarter, the company had reported an adjusted loss of 9 cents per share. The reported loss excludes share-based compensation expense, income tax benefit and non-cash interest expense. Including these items, the company incurred a loss of 27 cents per share in the first quarter compared with a loss of 24 cents in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Total revenues in the first quarter came in at $15.4 million, also missing the Zacks Consensus Estimate of $16 million. Revenues, however, rose 6.2% year over year owing to increased collaboration revenues from partner Viatris VTRS. Year to date, shares of Theravance have risen 5.2% against the industry’s decline of 3.1%.Zacks Investment Research Image Source: Zacks Investment Research TBPH's Q1 Results in Detail The top line fully comprised Viatris’ collaboration revenues in relation to Yupelri (revefenacin) sales. Theravance and Viatris have collaborated for the development and commercialization of Yupelri, which is approved in the United States for the maintenance treatment of patients with chronic obstructive pulmonary disease. Viatris and Theravance share U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris' collaboration revenues include Theravance’s 35% share of net sales of Yupelri, as well as its proportionate amount of the total shared costs incurred by the two companies. VTRS recognizes product sales from Yupelri and also owns a stake in Theravance. Viatris recorded $58.3 million in U.S. net sales of Yupelri in the first quarter, up 6% year over year. Theravance has some royalty interest in GSK plc’s GSK chronic obstructive pulmonary disease (COPD) medicine, Trelegy Ellipta. In February 2025, TBPH earned a $50 million milestone payment from partner Royalty Pharma based on Trelegy Ellipta’s net sales of $3.46 billion in 2024, as reported by GSK. TBPH is entitled to receive a similar milestone payment of $50 million from partner Royalty Pharma if Trelegy Ellipta’s global net sales total ~$3.41 billion in 2025. In 2022, Theravance sold its economic interest in sales-based royalty rights on worldwide net sales of GSK’s Trelegy to Royalty Pharma while retaining some rights to certain future milestone payments. Research and development expenses (excluding share-based compensation) totaled $10.4 million, up almost 40.5% from the year-ago quarter’s level. Selling, general and administrative expenses (excluding share-based compensation) increased around 13.2% year over year to $14.6 million. Story Continues As of March 31, 2025, Theravance had cash, cash equivalents and marketable securities worth $130.9 million compared with $88.4 million as of Dec. 31, 2024. TBPH's 2025 Financial Guidance Theravance reaffirmed its financial guidance for 2025. The company continues to expect adjusted R&D expenses (excluding share-based compensation) in the $32-$38 million range in 2025. Adjusted SG&A expenses (excluding share-based compensation) are projected between $50 million and $60 million. Theravance continues to expect share-based compensation expenses of $18-$20 million in 2025. TBPH expects both adjusted losses and cash burn in 2025 to be similar to 2024 levels. TBPH's Pipeline & Other Updates Theravance is developing an investigational candidate, ampreloxetine, a norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a progressive brain disorder. The phase III CYPRESS study is evaluating ampreloxetine for nOH MSA. The CYPRESS study is expected to complete patient enrollment by late summer. Top-line data from the same is expected six months after enrollment is completed. TBPH plans to submit a new drug application (NDA) for ampreloxetine if the study data are found to be positive. Theravance Biopharma, Inc. Price, Consensus and EPS SurpriseTheravance Biopharma, Inc. Price, Consensus and EPS Surprise Theravance Biopharma, Inc. price-consensus-eps-surprise-chart | Theravance Biopharma, Inc. Quote TBPH's Zacks Rank & Stock to Consider Theravance currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is ANI Pharmaceuticals, Inc. ANIP, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 29.4%. ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.32%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK):Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP):Free Stock Analysis Report Theravance Biopharma, Inc. (TBPH):Free Stock Analysis Report Viatris Inc. (VTRS):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...